Skip to content Skip to footer
Thoughtspot_Selina-Gran

Bridging the Gap Between Conventional and Integrative Medicine

Conventional medicine plays a crucial role in diagnosing, treating, and managing diseases through evidence-based interventions, including medications, surgeries, and other standardized treatments. However, there is a growing interest in integrative medicine, which combines conventional treatments with scientifically backed complementary therapies. This shift reflects a broader movement toward patient-centered, holistic healthcare that prioritizes both symptom relief…

Read more

Incyte and Syndax

Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab-csfr) to Treat Chronic Graft-Versus-Host Disease (GvHD) 

Shots:    Based on P-II (AGAVE-201) study, Niktimvo got FDA approval to treat chronic GvHD patients who failed at least two lines of previous therapy Niktimvo patients (0.3 mg/kg, Q2W, n=79) achieved 75% ORR in 6mos. with 1.5mos. mToR; 60% maintained response at 12mos. Study also met key exploratory EPs, 56% patients achieved ≥7-point improvement in…

Read more

VIEWPOINTS_Björn Mellgård_2023

Björn Mellgård shares insights from the Pivotal Phase III data of TAK-755 for congenital thrombotic thrombocytopenic purpura (cTTP)

Shots: Björn Mellgård Vice President and Global Program Lead, TTP Program, Takeda, shares insights from the P-III data of TAK-755 for the treatment of cTTP  Björn eloquently shares the highlights of the study design for TAK-755, safety and efficacy outcomes, and goes on to share an update from the P-IIIb continuation trial evaluating TAK-755  With…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]